湖南华纳大药厂股份有限公司自愿披露关于撤回药品注册申请的公告

Core Points - Hunan Warner Pharmaceutical Co., Ltd. has voluntarily disclosed the withdrawal of its drug registration application for Arolol Hydrochloride Tablets [1] - The National Medical Products Administration has approved the termination of the drug registration application [1] - The drug is primarily used for treating primary hypertension (mild to moderate), angina pectoris, tachycardia, and essential tremor [1] Summary by Sections - Drug Registration Application - The company submitted the application for Arolol Hydrochloride Tablets in April 2024 and received acceptance [1] - After careful consideration and alignment with its R&D strategy, the company decided to withdraw the application [1] - Impact on Business - The withdrawal of the drug registration application will not have a significant impact on the company's current or future operations and performance [1]